St. John's Wort constituents modulate p-glycoprotein transport activity at the blood-brain barrier

Pharmaceutical Research

Volumn 27, Issue 5, 2010, Pages 811-822

  Ott, Melanie ^a   Huls, Miriam ^b   Cornelius, Michael G ^c   Fricker, Gert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Blood brain barrier; P glycoprotein; Protein kinase C; Regulation; St. John's wort

Indexed keywords

GLYCOPROTEIN P; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PROTEIN KINASE C; QUERCETIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CAPILLARY ENDOTHELIUM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; ENDOTHELIUM CELL; EX VIVO STUDY; IMMUNOCHEMISTRY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SWINE; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CAPILLARIES; CELLS, CULTURED; CYCLOSPORINE; ENDOTHELIAL CELLS; FLUORESCEINS; FLUORESCENT DYES; HYPERICUM; IMMUNOHISTOCHEMISTRY; P-GLYCOPROTEIN; PROTEIN KINASE C; QUERCETIN; SIGNAL TRANSDUCTION; SWINE;

EID: 77953285105     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0074-1     Document Type: Article

References (43)

1. Linde K, Berner M, Egger M, Mulrow C. St John's wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry. 2005;186:99-107. (Pubitemid 40193777)
2. Saller R, Melzer J, Reichling J. St. John's Wort (Hypericum perforatum): a plurivalent raw material for traditional and modern therapies. Forsch Komplementarmed Klass Naturheilkd. 2003;10 Suppl 1:33-40. (Pubitemid 36750696)
3. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136:42-53.
4. Tilburt JC, Emanuel EJ, Miller FG. Does the evidence make a difference in consumer behavior? Sales of supplements before and after publication of negative research results. J Gen Intern Med. 2008;23:1495-1498
5. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol. 2000;33:853-855
6. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355:548-549 (Pubitemid 30088678)
7. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf. 2004;27:773-797 (Pubitemid 39243561)
8. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des. 2008;14:1723-1742
9. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA. 2000;97:7500-7502
10. Ott M, Fricker G, Bauer B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther. 2009;329:141-149
11. Quiney C, Billard C, Faussat AM, Salanoubat C, Kolb JP. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells. Leuk Lymphoma. 2007;48:1587-1599 (Pubitemid 47272809)
12. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002;71:414-420 (Pubitemid 34701348)
13. Weber CC, Kressmann S, Fricker G, Muller WE. Modulation of P-glycoprotein function by St John's wort extract and its major constituents. Pharmacopsychiatry 2004;37:292-298 (Pubitemid 39587057)
14. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001;134: 1601-1608
15. Kocanova S, Hornakova T, Hritz J, Jancura D, Chorvat D, Mateasik A, et al. Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006;82:720-728 (Pubitemid 44032792)
16. Granado-Serrano AB, Angeles Martin M, Bravo L, Goya L, Ramos S. Time-course regulation of quercetin on cell survival/proliferation pathways in human hepatoma cells. Mol Nutr Food Res. 2008;52:457-464
17. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol. 2004;66:387-394 (Pubitemid 39329237)
18. Bates ME, Bertics PJ, Calhoun WJ, Busse WW. Increased protein kinase C activity in low density eosinophils. J Immunol. 1993;150:4486-4493 (Pubitemid 23133725)
19. Castro AF, Horton. JK, Vanoye CG, Altenberg GA. Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem Pharmacol. 1999;58:1723-1733
20. Schramm U, Fricker G, Wenger R, Miller DS. P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. Am J Physiol. 1995;268:F46-52. (Pubitemid 124005459)
21. Miller DS, Graeff C, Droulle L, Fricker S, Fricker G. Xenobiotic efflux pumps in isolated fish brain capillaries. Am J Physiol Regul Integr Comp Physiol. 2002;282:R191-8.
22. Bauer B, Miller DS, Fricker G. Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm Res. 2003;20:1170-1176 (Pubitemid 36951841)
23. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol. 2000;58:1357-1367
24. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein upregulation. Mol Pharmacol. 2006;70:1212-1219
25. Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood). 2005;230:118-127
26. Essodaigui M, Broxterman HJ, Garnier-Suillerot A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry. 1998;37:2243-2250 (Pubitemid 28119297)
27. Hollo Z, Homolya L, Hegedus T, Muller M, Szakacs G, Jakab K, et al. Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1. Anticancer Res. 1998;18:2981-2987
28. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000;83:375-383 (Pubitemid 30453579)
29. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol. 2004;66:413-419 (Pubitemid 39329239)
30. von Eggelkraut-Gottanka SG, Abu Abed S, Muller W, Schmidt PC. Quantitative analysis of the active components and the by-products of eight dry extracts of Hypericum perforatum L. (St John's Wort). Phytochem Anal. 2002;13:170-176 (Pubitemid 34567857)
31. Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H, et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol. 2000;395:193-201. (Pubitemid 30254368)
32. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol. 2007;71:667-675 (Pubitemid 46294078)
33. Hartz AM, Bauer B, Block ML, Hong JS, Miller DS. Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. FASEB J. 2008;22:2723-2733
34. Bates SE, Currier SJ, Alvarez M, Fojo AT. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 1992;31:6366-6372
35. Nishizuka Y. Studies and prospectives of protein kinase C in signal transduction. Nippon Ketsueki Gakkai Zasshi. 1988;51:1321-1326
36. Ferriola PC, Cody V, Middleton Jr E. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol. 1989;38:1617-1624
37. Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT. Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 1993;32:9156-9164 (Pubitemid 24186238)
38. Fu D, Bebawy M, Kable EP, Roufogalis BD. Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: implications in multidrug resistance in cancer. Int J Cancer. 2004;109:174-181 (Pubitemid 38240917)
39. Labroille G, Belloc F, Bilhou-Nabera C, Bonnefille S, Bascans E, Boisseau MR, et al. Cytometric study of intracellular P-gp expression and reversal of drug resistance. Cytometry 1998;32: 86-94. (Pubitemid 28246755)
40. Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung 2005;55:15-22. (Pubitemid 40175249)
41. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavail-ability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998;31 Suppl 1:36-43. (Pubitemid 28294224)
42. Franklin M, Chi J, McGavin C, Hockney R, Reed A, Campling G, et al. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry. 1999;46:581-584 (Pubitemid 29369087)
43. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30 Suppl 2:94-101.